The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate ...

The fully funded study is expected to evaluate TNF-a levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia. TNFA is ...

The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants ...

For more than 15 years, researchers at the Icahn School of Medicine at Mount Sinai have worked tirelessly to find a solution ...

Phase 3 trial results Tapinarof cream 1% (Organon) Aryl hydrocarbon receptor agonist For the treatment of atopic dermatitis in adults and children 2 years and older. PDUFA extended Linerixibat ...

And if you have any idea what that means, it might be too late for you. Fortnite is no stranger to collaborations, from ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.

William Blair analyst Sami Corwin maintained a Buy rating on Neurogene (NGNE – Research Report) yesterday. The company’s shares opened today at ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...